Last updated: 11/07/2018 09:08:40
Study STF115287, a Clinical Confirmation Study of GSK2585823 in the Treatment of Acne Vulgaris in Japanese Subjects
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: Study STF115287, a Clinical Confirmation Study of GSK2585823 (Clindamycin 1%-Benzoyl Peroxide 3% Gel) in the Treatment of Acne Vulgaris in Japanese Subjects. - A multicenter, randomized, single-blind, active-controlled, parallel-group study -
Trial description: This is a multicenter, randomized, single-blinded (investigator’s blinded), active-controlled (clindamycin [CLDM] 1% gel), parallel-group study in Japanese subjects with acne vulgaris to demonstrate the efficacy of GSK2585823 (CLDM 1%-benzoyl peroxide [BPO] 3% gel) when applied once or twice daily for 12 weeks. This study will also evaluate the safety of GSK2585823 when applied topically either once or twice daily for 12 weeks.
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
Single (Investigator)
Allocation:
Randomized
Primary outcomes:
Absolute change from Baseline to Week 12 in total lesion counts.
Timeframe: Baseline (Day 1) and Week 12
Secondary outcomes:
Absolute change from Baseline to Weeks 1, 2, 4, and 8 in total lesion counts
Timeframe: Baseline (Day 1) and Weeks 1, 2, 4, and 8
Absolute change from Baseline to Weeks 1, 2, 4, 8, and 12 in inflammatory and non-inflammatory lesion counts
Timeframe: Baseline (Day 1) and Weeks 1, 2, 4, 8, and 12
Percent change from Baseline to Weeks 1, 2, 4, 8, and 12 in total, inflammatory, and non- inflammatory lesion counts
Timeframe: Baseline (Day 1) and Weeks 1, 2, 4, 8, and 12
Percentage of participants with a minimum 2-grade improvement from Baseline to Week 12 in Investigator’s Static Global Assessment (ISGA) score
Timeframe: Baseline (Day 1) and Week 12
Percentage of participants with an ISGA score of 0 (clear) or 1 (almost clear) at Weeks 1, 2, 4, 8, and 12
Timeframe: Week 1, 2, 4, 8, and 12
Percentage of participants who have a reduction of at least 50 percent in total lesions
Timeframe: Baseline (Day 1) and Week 1, 2, 4, 8, and 12
Minimum Inhibitory Concentration (MIC) of clinical isolates to antibiotics CLDM and Nadifloxacin (NDFX)
Timeframe: Baseline (Day 1) and Week12
Change in Investigator Assessment of Tolerability (Erythema, Dryness and Peeling) from Baseline to Weeks 1, 2, 4 and 8 and 12
Timeframe: Baseline (Day 1) and Week 1, 2, 4, 8, and 12
Change in Participant Assessment of Tolerability ( Itching and Burning/Stinging ) from Baseline to Weeks 1, 2, 4, 8 and 12
Timeframe: Baseline (Day 1) and Week 1, 2, 4, 8 and 12
Interventions:
Enrollment:
800
Primary completion date:
2012-02-08
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Makoto Kawashima, Masashiro Yamada, Hirofumi Hashimoto, Alessandra Sáenz Alio and Makoto Ono.Clindamycin phosphate 1.2%–benzoyl peroxide 3% fixed-dose combination gel is effective, safe and well tolerated for the treatment of acne vulgaris in Japanese patients: a phase III, multicentre, randomised, single-blinded, active-controlled, parallel-group study.Br J Dermatol.2015;172(2):494-503
Medical condition
Acne Vulgaris
Product
benzoyl peroxide, benzoyl peroxide/clindamycin phosphate, clindamycin phosphate
Collaborators
Not applicable
Study date(s)
September 2011 to August 2012
Type
Interventional
Phase
3
Participation criteria
Sex
Female & Male
Age
12 - 45 years
Accepts healthy volunteers
No
- Male or female subjects 12 to 45 years (inclusive) of age in good general health.
- Subjects must have both on the face:
- Have any nodule-cystic lesions at baseline.
- Are pregnant or breast-feeding.
Inclusion and exclusion criteria
Inclusion criteria:
- Male or female subjects 12 to 45 years (inclusive) of age in good general health.
- Subjects must have both on the face: A) A minimum of 17 but not more than 60 inflammatory lesions (papules/pustules), including nasal lesions. And B) A minimum of 20 but not more than 150 non-inflammatory lesions (open/closed comedones), including nasal lesions.
- An ISGA score of 2 or greater at baseline.
- Females of childbearing potential and women who are less than 2 years from their last menses must agree to use the contraception.
- The ability and willingness to follow all study procedures and attend all scheduled visits.
- The ability to understand and sign a written informed consent form (Written informed consent must be obtained also from the parent or guardian in case of subject under 20 years of age at the time of given consent).
Exclusion criteria:
- Have any nodule-cystic lesions at baseline.
- Are pregnant or breast-feeding.
- Have a history or presence of regional enteritis, inflammatory bowel disease (e.g., ulcerative colitis, pseudomembranous colitis, chronic diarrhea or antibiotic-associated colitis) or similar symptoms.
- Used any of the following agents on the face within the previous 2 weeks:Topical antibiotics (or systemic antibiotics);Topical anti-acne medications (e.g., BPO, azelaic acid, resorcinol, salicylates);Abradants, facials, or peels containing glycolic or other acids;Masks, washes or soaps containing BPO, sulfacetamide sodium, or salicylic acid;Non-mild facial cleansers (e.g., facial scrub, cleansers containing agents with anti-inflammatory action); Moisturizers that contain retinol, salicylic acid, or α- or β-hydroxy acids;Astringents and toner (Subjects are allowed to enroll in this study, if the subject has been on treatment for more than 2 consecutive weeks prior to start of investigational product use).
- Used the following agents on the face or performed the following procedure within the previous 4 weeks:Topical corticosteroids (Use of inhaled, intra-articular, or intra-lesional steroids other than for facial acne is acceptable);Facial procedure (such as chemical or laser peel, microdermabrasion, blue light treatment, etc.).
- Used systemic retinoids within the previous 6 months or topical retinoids on the face within the previous 6 weeks.
- Received treatment with estrogens, androgens, or anti-androgenic agents within the previous 12 weeks (Subjects who have been treated with the above agents for more than 12 consecutive weeks prior to start of investigational product are allowed to enrol as long as they do not expect to change dose, drug, or discontinue use during the study).
- Used any medication that in the opinion of the investigator may affect this clinical study or evaluation of the study.
- Plan to use medications that are reported to exacerbate acne (e.g., mega-doses of certain vitamins, such as vitamin D [>2000 IU/day] and vitamin B12 [>1 mg/day], corticosteroids*, androgens, haloperidol, halogens [e.g., iodide and bromide], lithium, hydantoin, and phenobarbital). *: except the using of topical corticosteroids (e.g., inhaled, intra-articular, or intra-lesional steroids) other than for facial acne.
- Have a known hypersensitivity or have had previous allergic reaction to any of the components of the investigational product.
- Used any investigational therapy within the previous 12 weeks, or plan to participate in another clinical study at the same time.
- Participated in Japanese clinical studies planned by GlaxoSmithKline K.K. in the development of investigational products for acne vulgaris.
- Are currently abusing drugs or alcohol.
- Have a significant medical history of being immunocompromised.
- People as follows and the family members:Employees of GlaxoSmithKline, contract research organization (CRO) or site management organization (SMO);Investigators.
- Have other conditions that would put the subject at unacceptable risk for participation in the study.
Trial location(s)
Showing 1 - 6 of 26 Results
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Study complete
Actual primary completion date
2012-02-08
Actual study completion date
2012-02-08
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website